This study of the 2.25 mm PROMUS Element Stent reconfirms our commitment to providing a complete range of stenting solutions and sizes for physicians and their patients." Boston Scientific received CE ...

Approval marks transition to internally manufactured everolimus eluting stent in the U.S.NATICK, Mass., Boston Scientific Corporation announces U.S. Food and Drug Administration (FDA) approval for the ...

Boston Scientific has announced the European market launch of the PROMUS Element Plus stent, which incorporates platinum chromium allow and features a catheter delivery system.

The PROMUS Element Stent, whichreceived CE Mark in October 2009, is Boston Scientific's third-generationdrug-eluting stent technology and incorporates a platinum chromium alloy withan innovative ...

The PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System (Boston Scientific) was designed specifically for coronary stenting. It utilizes a proprietary platinum chromium ...

Boston Scientific Launches PROMUS® Element and TAXUS® Element Stent Systems in IndiaCompany's third-generation drug-eluting stents now available in rapidly growing marketFeb 17, 2011 NATICK, ...

Boston Scientific Corp. BSX late Tuesday said its key "Promus Element" heart stent has gained U.S. FDA approves Boston Scientific's new heart stent. Share. Resize. Skip to main content.

DES sales have benefited from the earlier-than-expected approval of Promus Element plus in the US (in November 2011) along with launch of the product in Japan and Canada, both in March 2012 ...

Boston Scientific Corporation (NYSE: BSX) announces first patient use and European market launch of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System. The first ...

Medical-device maker Boston Scientific yesterday released data from a clinical trial showing that its Promus Element drug-eluting stent showed advantages over Abbott's Xience V drug-eluting stent with ...

Two-year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent Boston ...

Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.